Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target […]
Moody Aldrich Partners LLC lessened its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 44.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,873 shares of the company’s stock after selling 64,980 shares during the period. Moody […]
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average […]
Mizuho Markets Americas LLC lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 5.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 94,198 shares of the company’s stock after purchasing an additional 4,600 shares during the quarter. Mizuho Markets […]
Mizuho restated their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report released on Monday morning, Benzinga reports. The firm currently has a $60.00 target price on the stock. Several other equities analysts have also recently issued reports on BBIO. BTIG Research raised their price target on BridgeBio Pharma from […]